Ayman Al-Hendy to Phenylurea Compounds
This is a "connection" page, showing publications Ayman Al-Hendy has written about Phenylurea Compounds.
Connection Strength
2.659
-
Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long-term extension study: A descriptive subgroup analysis in women with anemia at baseline. Int J Gynaecol Obstet. 2024 May; 165(2):431-441.
Score: 0.893
-
Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021 02 18; 384(7):630-642.
Score: 0.719
-
A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy. Pain Manag. 2024 Sep; 14(9):469-476.
Score: 0.232
-
Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol. 2024 02; 230(2):237.e1-237.e11.
Score: 0.216
-
A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies. Pain Manag. 2023 Apr; 13(4):205-211.
Score: 0.210
-
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022 06 01; 139(6):1070-1081.
Score: 0.195
-
An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
Score: 0.192